Strategic Use of Epitope Matching to Improve Outcomes

Transplantation

Volumn 100, Issue 10, 2016, Pages 2048-2052

  Wiebe, Chris ^a   Nickerson, Peter ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DONOR SPECIFIC ANTIBODY; EPITOPE; HLA ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; TACROLIMUS; UNCLASSIFIED DRUG;

ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT SURVIVAL; HLA MATCHING; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PERSONALIZED MEDICINE; PREMATURE MORTALITY; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; REVIEW; TRANSPLANT GLOMERULOPATHY; ADVERSE EFFECTS; DONOR; EPITOPE MAPPING; GRAFT REJECTION; HISTOCOMPATIBILITY TEST;

EPITOPE MAPPING; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; TISSUE DONORS;

EID: 84976541877     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001284     Document Type: Review

References (36)

1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant. 2011;11: 450-462.
2. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527-535.
3. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the 'troubled transplant': data from the Dekaf study. Am J Transplant. 2010;10:324-330.
4. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010;90:68-74.
5. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157-1167.
6. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant. 2015;15:2921-2930.
7. Cosio FG, El Ters M, Cornell LD, et al. Changing kidney allograft histology early posttransplant: prognostic implications of 1-year protocol biopsies. Am J Transplant. 2016;16:194-203.
8. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant. 2012;12:1192-1198.
9. El Ters M, Grande JP, Keddis MT, et al. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant. 2013;13: 2334-2341.
10. Chemouny JM, Suberbielle C, Rabant M, et al. De novo donor-specific human leukocyte antigen antibodies in nonsensitized kidney transplant recipients after T cell-mediated rejection. Transplantation. 2015; 99:965-972.
11. Merrill JP, Murray JE, Harrison JH, et al. Successful homotransplantation of the human kidney between identical twins. JAMA. 1956;160:277-282.
12. Takemoto SK, Terasaki PI, Gjertson DW, et al. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl JMed. 2000;343:1078-1084.
13. Duquesnoy RJ. HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol. 2002;63:339-352.
14. El-Awar N, Cook D, Terasaki PI. HLA class I epitopes: A and B loci. Clin Transpl. 2006:79-94.
15. Kosmoliaptsis V, Bradley JA, Sharples LD, et al. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAmatchmaker. Transplantation. 2008;85:1817-1825.
16. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol. 2006;67: 847-862.
17. Duquesnoy RJ, Askar M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol. 2007;68:12-25.
18. Kosmoliaptsis V, Sharples LD, Chaudhry AN, et al. Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation. 2011; 91:183-190.
19. Kosmoliaptsis V, Mallon DH, Chen Y, et al. Alloantibody responses after renal transplant failure can be better predicted by donor-recipient HLA amino acid sequence and physicochemical disparities than conventional HLA matching. Am J Transplant. 2016;16:2139-2147.
20. Dankers MKA, Witvliet MD, Roelen DL, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation. 2004;77:1236-1239.
21. Wiebe C, Nickerson P. Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Curr Opin Organ Transplant. 2013;18:470-477.
22. Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching-a strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant. 2013;13:3114-3122.
23. Hricik DE, Formica RN, Nickerson P, et al. Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients. J Am Soc Nephrol. 2015;26:3114-3122.
24. Cosio FG, Gloor JM, Sethi S, et al. Transplant glomerulopathy. Am J Transplant. 2008;8:492-496.
25. Sapir-Pichhadze R, Tinckam K, Quach K, et al. HLA-DR and-DQ eplet mismatches and transplant glomerulopathy: a nested case-control study. Am J Transplant. 2014;15:137-148.
26. Silva E, Alba A, Castro A, et al. Evaluation of HLA Matchmaker compatibility as predictor of graft survival and presence of anti-HLA antibodies. Transplant Proc. 2010;42:266-269.
27. Kosmoliaptsis V, Sharples LD, Chaudhry A, et al. HLA class I amino acid sequence-based matching after interlocus subtraction and long-term outcome after deceased donor kidney transplantation. Hum Immunol. 2010;71:851-856.
28. Duquesnoy RJ, Takemoto S, de Lange P, et al. HLAmatchmaker: A molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A,B amino acid triplet level on kidney transplant survival. Transplantation. 2003;75:884-889.
29. Laux G, Mansmann U, Deufel A, et al. A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants. Transplantation. 2003;75:1527-1532.
30. Haririan A, Fagoaga O, Daneshvar H, et al. Predictive value of human leucocyte antigen epitope matching using HLAMatchmaker for graft outcomes in a predominantly African-American renal transplant cohort. Clin Transplant. 2006;20:226-233.
31. Wiebe C, Nevins TE, Robiner WN, et al. The synergistic effect of class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival. Am J Transplant. 2015;15:2197-2202.
32. Duquesnoy RJ, Awadalla Y, Lomago J, et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ, DP epitopes. Transpl Immunol 2008;18:352-360.
33. Kosmoliaptsis V, Chaudhry AN, Sharples LD, et al. Predicting HLA class I alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation. 2009;88:791-798.
34. Duquesnoy RJ, Howe J, Takemoto S. HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients. Transplantation. 2003;75:889-897.
35. Heidt S, Witvliet MD, Haasnoot GW, et al. The 25th anniversary of the Eurotransplant acceptable mismatch program for highly sensitized patients. Transpl Immunol. 2015;33:51-57.
36. Nguyen HD, Wong G, Howard K, et al. Modeling the benefits and costs of integrating an acceptable HLA mismatch allocation model for highly sensitized patients. Transplantation. 2014;97:769-774.